WR Hambrecht comments on Nektar Therapeutics (Nasdaq: NKTR), saying the stock could be a winner from today's Neurocrine Biosciences Inc ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE